Head of ICT
As a recognised technology leader, known for crafting the requisite [...]
Head of MedTech
Ben brings first-hand appreciation of the many challenges involved in taking medical devices through research, development, transfer to manufacture, validation, verification and regulatory approval.
Today we have released feasibility test results for our innovative Occoris® inhaler engine concept, demonstrating a significant improvement in the efficiency of drug delivery to the deep lung compared to typical dry powder inhaler (DPI) devices.
Some 600 delegates braved the heat of the Arizona desert to attend the...
Designed primarily for delivering systemic treatments beyond the typically inhaled topical asthma and COPD, such as vaccines, pain relief and insulin, the Occoris™ ‘engine’ is ultra-small, active and achieves very accurate and repeatable delivery of API-only formulations.
The new ISO20072 standard for inhalers was published a few years ago...
A new Dry Powder Inhaler (DPI), designed and developed by Valois Pharma with the support of Team Consulting, was presented for the first time at the recent Drug Delivery to the Lungs Conference in Edinburgh. Whilst offering excellent delivery performance, the Prohaler™ was designed from the outset with the user in mind and is completely intuitive to use.
Team Consulting and Valois Pharmaceutical Division today announced they have embarked upon a major development programme to produce a novel breath-actuated multi-dose Dry Powder Inhaler (DPI).
The 'Bead Inhaler' will utilise a unique dispersion technology proven to deliver excellent aerosolisation performance, reproducible emitted dose and high fine particle fraction. A novel drug storage and release technology is also being developed. In addition to offering excellent delivery performance and moisture protection with a wide range of formulations, the inhaler will be compact and simple to use.